NCT06081595View on ClinicalTrials.gov

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2026

Conditions
Relapsed Ovarian Cancer
Interventions
DRUG

Fluzoparib

Fluzoparib 100mg bid

DRUG

Apatinib

Apatinib 375mg qd

All Listed Sponsors
lead

Jin Li

OTHER

NCT06081595 - Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment | Biotech Hunter | Biotech Hunter